For research use only. Not for therapeutic Use.
Prexasertib dimesylate（Cat No.:I015028）is an investigational dual inhibitor of checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2), enzymes that play critical roles in DNA damage response and cell cycle regulation. By inhibiting these kinases, prexasertib enhances the sensitivity of cancer cells to DNA-damaging agents, promoting apoptosis in tumors with defective repair mechanisms. It is being evaluated in clinical trials for various cancers, particularly those with genomic instability, such as pancreatic and ovarian cancers. Side effects may include myelosuppression and gastrointestinal issues, necessitating careful monitoring during treatment.
| Catalog Number | I015028 |
| CAS Number | 1234015-58-7 |
| Molecular Formula | C₂₀H₂₇N₇O₈S₂ |
| Purity | ≥95% |
| Target | Apoptosis |
| IUPAC Name | 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;methanesulfonic acid |
| InChI | InChI=1S/C18H19N7O2.2CH4O3S/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17;2*1-5(2,3)4/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25);2*1H3,(H,2,3,4) |
| InChIKey | HXYBEKZGRNUTBN-UHFFFAOYSA-N |
| SMILES | COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N.CS(=O)(=O)O.CS(=O)(=O)O |
| Reference | [1]. King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-1<br>[2]. Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7(3):473-483. |
